DETTI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 657
EU - Europa 654
AS - Asia 199
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 1.514
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 655
RU - Federazione Russa 416
IE - Irlanda 81
IT - Italia 80
HK - Hong Kong 75
SG - Singapore 55
SE - Svezia 38
CN - Cina 25
JO - Giordania 25
FI - Finlandia 11
IN - India 11
DE - Germania 9
GB - Regno Unito 9
KR - Corea 4
CA - Canada 2
CI - Costa d'Avorio 2
FR - Francia 2
GR - Grecia 2
PH - Filippine 2
UA - Ucraina 2
AT - Austria 1
AU - Australia 1
BR - Brasile 1
CZ - Repubblica Ceca 1
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
TR - Turchia 1
Totale 1.514
Salva come PNG Salva come JPEG
Città #
Santa Clara 284
Dublin 81
Chandler 80
Hong Kong 54
Singapore 44
Ashburn 29
New York 16
West Jordan 15
Florence 12
Helsinki 10
Moscow 10
Shanghai 10
Kent 8
Mumbai 7
Altamura 6
Lawrence 6
Milan 6
Los Angeles 5
Munich 5
Seattle 5
Yubileyny 5
Boston 4
Fairfield 4
Princeton 4
Pune 4
Rome 4
Seoul 4
Southwark 4
Wilmington 4
Brescia 3
Buffalo 3
Garden City 3
Pontedera 3
San Diego 3
Abidjan 2
Bologna 2
Cambridge 2
Empoli 2
Fiesole 2
Frankfurt am Main 2
Novate Milanese 2
Scarperia e San Piero 2
Thessaloniki 2
Toronto 2
Woodbridge 2
Ann Arbor 1
Arezzo 1
Bari 1
Cabanatuan City 1
Chiari 1
Colle di Val d'Elsa 1
Dalian 1
Gorgonzola 1
Hillsboro 1
Lappeenranta 1
London 1
Lucca 1
Medford 1
Nanjing 1
Norwalk 1
Padova 1
Paris 1
Ponte Buggianese 1
Prague 1
Quezon City 1
Romola 1
Rui'an 1
Sassari 1
Shenzhen 1
Sydney 1
São Paulo 1
Vienna 1
Wandsworth 1
Washington 1
Wuhan 1
Totale 797
Salva come PNG Salva come JPEG
Nome #
Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275) 75
Regorafenib in glioblastoma recurrence: A case report 73
Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275) 70
Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature 68
Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature 66
May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk? 64
Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients 63
Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience 63
Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery 63
Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis 62
Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy 62
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials 61
Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719) 60
Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results 59
Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis 58
Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature 57
PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study 55
Killing two birds with a stone: how to maximise benefit from metastasis-directed therapy and modern systemic treatment in oligometastatic hormone sensitive prostate cancer 55
Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review 53
Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years 48
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting 48
Synchronous bilateral testicular germ cell tumour: Case report and review of the literature 46
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience 45
Three Months' PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736) 44
Single-fraction stereotactic body radiotherapy for oligometastatic lymph node relapse in prostate cancer 38
Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort 38
Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques 33
Totale 1.527
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 15 3 0 0 4 1 1 6 9
2022/2023330 10 27 8 18 35 80 53 25 60 1 5 8
2023/2024273 11 19 26 21 14 43 17 67 2 22 18 13
2024/2025885 43 142 92 252 356 0 0 0 0 0 0 0
Totale 1.527